Lakefront Biotherapeutics NV LKFT

Latest FY: 2025 Healthcare Biotechnology
Market Price $29.01
Market Cap $1.91B
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑303.5% YoY
$1.11B
3-Yr CAGR: 30.1%
Net Income ↑333.1% YoY
$320.88M
Net Margin: 28.9%
Free Cash Flow ↑22.2% YoY
-$13.33M
FCF Yield: -0.70%
EPS (Diluted)
N/A
Basic: N/A
Return on Equity Efficiency
N/A
ROA: 9.4%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (LKFT)

All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
  • FY 2018: Revenue YoY (+127.3%) is identical to Gross Profit YoY (+127.3%). Verify the underlying Revenue and Gross Profit values for FY 2018 and FY 2017.
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $129.5M $10.3M $54.0M 0.00% $1.8M $-2.7M
FY 2017 $127.1M -1.9% $111.0M $-115.7M -314.2% 0.00% $0.2M $-5.1M -89.7%
FY 2018 $288.8M +127.3% $252.3M $-29.3M +74.7% 0.00% $0.0M $-10.4M -103.1%
FY 2019 $845.0M +192.5% $444.0M $149.8M +612.1% 0.00% $0.1M $-22.3M -115.0%
FY 2020 $478.1M -43.4% $417.6M $-305.4M -303.8% 0.00% $1.4M $-41.2M -84.4%
FY 2021 $484.8M +1.4% $473.2M $-103.2M +66.2% 0.00% $0.7M $-53.5M -30.0%
FY 2022 $505.3M +4.2% $493.2M $-218.0M -111.2% 0.00% $4.4M $-23.0M +57.1%
FY 2023 $239.7M -52.6% $221.7M $211.7M +197.1% 0.00% $8.2M $-10.5M +54.1%
FY 2024 $275.6M +15.0% $240.8M $74.1M -65.0% 0.00% $-0.4M $-17.1M -62.5%
FY 2025 $1,112.2M +303.5% $1,082.5M $320.9M +333.1% 0.00% $0.4M $-13.3M +22.2%
$

Valuation

Market Price $29.01
Market Cap $1.91B
Enterprise Value N/A
P/E Ratio N/A
P/B Ratio N/A
FCF Yield -0.70%
Dividend Yield 0.00%
Shares Outstanding 65,897,071
%

Profitability & Margins

Gross Margin 97.33%
Operating Margin 26.53%
Net Margin 28.85%
Return on Equity (ROE) N/A
Return on Assets (ROA) 9.42%
Asset Turnover 0.33x
Revenue 3-Yr CAGR 30.08%
🛡️

Financial Health & Liquidity

Current Ratio N/A
Cash Ratio N/A
Debt / Equity N/A
Debt / Assets 0.000
Cash & Equivalents N/A
Total Debt N/A
Book Value / Share N/A
💧

Cash Flow Efficiency

Operating Cash Flow $372.00K
Capital Expenditures (CapEx) $13.70M
Free Cash Flow -$13.33M
OCF / Revenue 0.03%
FCF / Revenue -1.20%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) N/A
EPS (Basic) N/A
Dividends / Share N/A
Book Value / Share N/A
EPS YoY Growth N/A
🏛️

Balance Sheet (FY 2025)

Total Assets $3.41B
Total Liabilities $170.65M
Stockholders' Equity N/A
Current Assets N/A
Current Liabilities N/A